A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with spinocerebellar ataxia types 1, 3 and Huntington’s disease

3 and Huntington's disease, Spinocerebellar ataxia types 1

 Incidence and dose relationships of treatment-related: o AEs, o SAEs, o AESI o Severe events (NCI- CTCAE Grade 3 or higher).,  Changes in clinical safety parameters including physical and neurological examinations, vital signs, body weight, ECG, cardiac monitoring, suicidal ideation and behaviour risk monitoring by the C-SSRS, and review of structural MRI scans,  Changes in laboratory safety parameters in blood (haematology, haemostasis, and clinical chemistry), CSF (cell counts, protein, and glucose), and urine (urinalysis),  Adverse changes in clinical status based on exploratory clinical, biochemical and neuroimaging assessments

 The CSF concentration-time profile of VO659, including the derived PK parameter of elimination t1/2, if possible,  The plasma concentration-time profile of VO659, including the derived PK parameters such as the area under the curve, peak plasma concentration t1/2.

No related papers found yet.

Denmark, France, Germany, Netherlands